menu search

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...

November 3, 2023, 11:30 pm

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...

November 3, 2023, 11:30 pm

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...

November 3, 2023, 11:30 pm

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...

November 3, 2023, 11:30 pm

Aligos therapeutics to host kol event to discuss alg-000184 phase 1, aasld late breaker data

November 16 Event to feature KOL perspective on Emerging HBV therapies SOUTH SAN FRANCISCO, Calif., Nov...

November 3, 2023, 8:30 pm

Taysha gene therapies: tsha-102's potential is a 'buy'

Taysha Gene therapies is a biotech stock focused on developing gene ...

November 3, 2023, 7:41 pm

Bruise treatment market size to reach usd 444 million by 2031, at a 3.5 % cagr | by tmr

Emerging trends in regenerative medicine and stem cell therapies are expected to offer innovative solut...

November 3, 2023, 12:30 pm

Longeveron to report third quarter 2023 results and provide corporate update on november 10, 2023

MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company d...

November 3, 2023, 12:00 pm

The ensign group acquires post acute care campus in texas

SAN JUAN CAPISTRANO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of co...

November 3, 2023, 10:00 am

Astria therapeutics to present new star-0215 data at the 2023 american college of allergy, asthma, and immunology annual scientific meeting

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing ...

November 3, 2023, 8:10 am

Cidara therapeutics provides corporate update and reports third quarter 2023 financial results

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on developing targeted ...

November 2, 2023, 8:15 pm

Regenxbio: biotech to watch with 2 possible accelerated approval pathways

Regenxbio Inc. is making progress in its pipeline, aiming to have five gene therapies in late-stage tes...

November 2, 2023, 5:33 pm

Intra-cellular therapies reports third quarter 2023 financial results and raises 2023 caplyta sales guidance

Q3 2023 total revenues increased to $126.2 million, compared to $71.9 million in the same period in 2022 CAPLYTA Q3 2023 net product sales were $125.8...

November 2, 2023, 11:30 am

Ocugen to host conference call on thursday, november 9 at 8:30 a.m. et to discuss business updates and third quarter 2023 financial results

MALVERN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, ...

November 2, 2023, 11:30 am

Clearside biomedical announces presentations at the american academy of ophthalmology 2023 annual meeting

– Clinical Data Utilizing Clearside’s Suprachoroidal Delivery Technology to be Featured in Multiple Oral and Poster Presentations – ALPHARETTA, ...

November 2, 2023, 11:05 am

In8bio to present new positive data from phase 1 trial of inb-100 at 2023 american society of hematology (ash) annual meeting

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta ...

November 2, 2023, 9:17 am

Olema oncology to participate in upcoming investor conferences in november

SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biop...

November 1, 2023, 8:27 pm

Siren biotechnology awarded $4m in grant funding from the california institute for regenerative medicine (cirm)

SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) — Siren Biotechnology, a gene therapy company pioneering Universal AAV Immuno-Gene ...

November 1, 2023, 4:46 pm

Cellectis to report third quarter 2023 financial results on november 6, 2023

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology compa...

November 1, 2023, 4:30 pm

Olema oncology to participate in upcoming investor conferences in november

SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage bioph...

November 1, 2023, 4:27 pm


Search within

Pages Search Results: